Errata
Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, for the Sitagliptin 036 Study Group: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30:1979–1987, 2007
In Table 2 of the article above, an asterisk was missing denoting a significant difference between the 1,000 mg metformin b.i.d. group and placebo. The corrected table appears on the following page. The online version reflects these changes.
View this table:
Table 2—
Efficacy end points following a meal tolerance test
- DIABETES CARE
